- Home
- CLOV vs PVLA Comparison
CLOV vs PVLA Comparison
Compare CLOV & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLOV | PVLA |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLOV | PVLA |
|---|---|---|
| Price | $1.98 | $121.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 17 |
| Target Price | $3.35 | ★ $145.24 |
| AVG Volume (30 Days) | ★ 5.8M | 270.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,371,131,000.00 | N/A |
| Revenue This Year | $41.68 | N/A |
| Revenue Next Year | $43.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.95 | $18.23 |
| 52 Week High | $4.52 | $114.69 |
Technical Indicators
Market Signals| Indicator | CLOV | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 32.15 | 76.79 |
| Support Level | N/A | $85.53 |
| Resistance Level | $2.78 | N/A |
| Average True Range (ATR) | 0.08 | 6.88 |
| MACD | 0.00 | 3.97 |
| Stochastic Oscillator | 10.42 | 100.00 |
Price Performance
Historical ComparisonAbout CLOV Clover Health Investments Corp.
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.